Information provided on this form must be typed or printed electronically and provided to an ris.
Date:26 November 2019
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan
Period of return:
From:
1 May 2019
To:
31 October 2019
Balance of unallotted securities under scheme(s) from previous return:
153,724
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
153,724
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date:26 November 2019
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares
Period of return:
From:
1 May 2019
To:
31 October 2019
Balance of unallotted securities under scheme(s) from previous return:
1,265,008
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):
429,913
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
835,095
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date:26 November 2019
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline 2009 Share Option Plan - ADS
Period of return:
From:
1 May 2019
To:
31 October 2019
Balance of unallotted securities under scheme(s) from previous return:
5,911,296
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):
519,880
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
5,391,416
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date:26 November 2019
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline plc Share Save Plan 2012
Period of return:
From:
1 May 2019
To:
31 October 2019
Balance of unallotted securities under scheme(s) from previous return:
2,326,896
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):
181,084
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
2,145,812
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
Attachments
Original document
Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 26 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2019 15:12:04 UTC
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.